|Videos|August 24, 2022
Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
Author(s)Sunandana Chandra, MD, MS
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
3
KTX-1001 Elicits Responses in Some With Multiple Myeloma
4
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
5